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Research during recent years has established nitric oxide as a unique signaling molecule
that plays important roles in the regulation of the cardiovascular, nervous, immune, and
other systems. Nitric oxide has also been implicated in the control of the secretion of
hormones by the pancreas, hypothalamus, and anterior pituitary gland, and evidence is
accumulating that it contributes to the regulation of the secretion of renin and vasopres-
sin, hormones that play key roles in the control of sodium and water balance. Several lines
of evidence have implicated nitric oxide in the control of renin secretion. The enzyme nitric
oxide synthase is present in vascular and tubular elements of the kidney, particularly in
cells of the macula densa, a structure that plays an important role in the control of renin
secretion. Guanylyl cyclase, a major target for nitric oxide, is also present in the kidney.
Drugs that inhibit nitric oxide synthesis generally suppress renin release in vivo and in
vitro, suggesting a stimulatory role for the L-arginine/nitric oxide pathway in the control of
renin secretion. Under some conditions, however, blockade of nitric oxide synthesis
increases renin secretion. Recent studies indicate that nitric oxide not only contributes to
the regulation of basal renin secretion, but also participates in the renin secretory.
responses to activation of the renal baroreceptor, macula densa, and beta adrenoceptor
mechanisms that regulate renin secretion• Histochemical and immunocytochemical stud-
ies have revealed the presence of nitric oxide synthase in the supraoptic and paraventricu-
lar nuclei of the hypothalamus and in the posterior pituitary gland. Colocalization of nitric
oxide synthase and vasopressin has been demonstrated in some hypothalamic neurons.
Nitric oxide synthase activity in the hypothalamus and pituitary is increased by maneuvers
known to stimulate vasopressin secretion, including salt loading and dehydration. Admin-
istration of L-arginine and nitric oxide donors in vitro and in vivo has variable effects on
vasopressin secretion, but the most common one is inhibition. Blockade of nitric oxide
synthesis has been reported to increase vasopressin secretion, but again variable results
have been obtained. An attractive working hypothesis is that nitric oxide serves a
neuromodulatory role as an inhibitor of vasopressin secretion. KEY WORDS: Nitric oxide;
nitricoxide synthase; renin secretion; vasopressin secretion; kidney; hypothalamus. , 1994
Academic Press. ]nc,
INTRODUCTION
An enormous amount of research performed during recent years has estab-
lished nitric oxide as a unique and important signaling molecule involved in
cell-to-cell communication and other functions throughout the body (for reviews
see 8, 10, 63, 70, 77, 111,128). It is now known that nitric oxide plays important
351 0091-3022.'94 $6.00
Copyright :i, 1994 by Academic Press, Inc.
All rights of reproduction in any form reserved.
https://ntrs.nasa.gov/search.jsp?R=19980211543 2020-06-15T23:57:28+00:00Z
352 IAN A. REID
roles in the cardiovascular, nervous, renal, and immune systems, but increasing
evidence indicates that its functions extend well beyond those systems. For
example, nitric oxide appears to play an important role in the regulation of
endocrine function, having been implicated in the control of the secretion of
hormones by the pancreas, hypothalamus, and anterior pituitary gland (24, 25,
45, 61, 98, 107, 115). Evidence is also accumulating that nitric oxide contributes
to the regulation of the secretion of renin and vasopressin, hormones that play
key roles in the control of sodium and water balance. The purpose of this review
is to summarize recent progress concerning the role of nitric oxide in the
secretion of these two hormones.
THE L-ARGININE/NITRIC OXIDE PATHWAY
The L-arginine/nitric oxide pathway is shown in Fig. 1. Nitric oxide is formed
from the terminal guanidino group of L-arginine by the enzyme nitric oxide
synthase (8, 63, 77). Three distinct isoforms of nitric oxide synthase have been
identified and their cDNA has been cloned and sequenced (38, 63, 65, 78). In
humans, the isoforms are encoded by three different genes each located on
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FIG. 1. The L-arginine/nitric oxide/cyclic GMP signaling pathway. Constitutive isoforms of
nitric oxide synthase (Types I and II) require calcium/calmodulin for activity; Type II| nitric oxide
synthase is expressed after induction by cytokines and other substances. Each isoform can be
inhibited by a variety of arginine analogs.
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differentchromosomes.Eachisoformcontainshemeat its activesiteandall
requirethecofactorsNADPH,tetrahydrobiopterin,flavinadeninedinucleotide,
andflavinmononucleotide.
TypeI nitric oxidesynthase(alsoreferredto as bNOSand nNOS)was
originally identifiedin neuronsand is distributedwidelyin the brain and
autonomicnervoussystem.It is expressedconstitutivelyandis activatedby
calciumboundto calmodulin.TypeII nitric oxidesynthase(iNOS)isexpressed
in macrophages,moothmuscle,and the liver after inductionby bacterial
lipopolysaccharideor cytokines.Expressionof this isoformrequiresprotein
synthesis,butenzymeactivityisnotdependentoncalcium.TypeIII nitricoxide
synthase(eNOS)wasoriginallyidentifiedinendothelialcellsbut it hasalsobeen
foundin kidneyepithelialcells.LikeTypeI nitric oxidesynthase,it isexpressed
constitutivelyand is activatedby calcium/calmodulin.TypeIII nitric oxide
synthaseisresponsibleforendothelium-dependentrelaxationofvascularsmooth
muscle.
Nitric oxideis quite diffusible,but is rapidlyinactivatedwith a half-lifeof
approximately5 s and is thought to function primarily in a paracrineor
autocrinefashion.A majortargetfornitricoxideissolubleguanylylcyclase(34).
Nitric oxidebindsto iron in the hemeat the activesiteof guanylylcyclase,
alteringthe conformationof the enzymeandtherebyincreasingits activity.
Stimulationof guanylylcyclaseactivity by nitric oxide in turn results in
increasedformationofcyclicguanosine3',5'-monophosphate(cyclicGMP)whose
targetsincludephosphodiesterases,ion channels,andacyclicGMP-dependent
proteinkinasethat mediatesmoothmusclerelaxation.
Nitric Oxide Synthase and Guanylyl Cyclase in the Kidney
The presence of Type I nitric oxide synthase in the kidney has been demon-
strated by immunocytochemistry and NADPH histochemistry (69, 79, 119,
129). The presence of Type I nitric oxide synthase mRNA has also been
demonstrated by in situ hybridization (79) and the polymerase chain reaction
(118). By these methods, abundant nitric oxide synthase has been demonstrated
in the macula densa (Fig. 2). This is of particular interest in view of the
important role of this structure in the control of renin secretion. Type I nitric
oxide synthase is also present in other tubular and vascular elements of the
kidney (69, 118). An inducible form of nitric oxide synthase is present in smooth
muscle and granular cells of the terminal afferent arteriole (119). Finally, Type
III nitric oxide synthase has been identified in LLC-PK1 kidney epithelial cells
(122).
Soluble guanylyl cyclase, a major target for nitric oxide (Fig. 1), is widely
distributed in the kidney in the glomerulus, renal tubules, and vascular system
(118). Intrarenal administration of inhibitors of nitric oxide decreases cyclic
GMP release (11, 113), while the nitric oxide donor sodium nitroprusside
increases it (51).
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FIG. 2. NADPH diaphorase staining of rabbit kidney. G, glomerulus; MD, macula densa; PT,
proximal tubule; DT.
These observations demonstrate that nitric oxide is synthesized in the kidney
where it acts to stimulate the formation of cyclic GMP.
Drugs Used to Investigate the L-Arginine/Nitric Oxide Pathway
Investigation of the function of the L-arginine/nitric oxide pathway has been
greatly facilitated by the availability of several groups of drugs (63, 89) (Table 1).
Of particular importance is a group of L-N_-substituted arginine analogs that are
competitive inhibitors of nitric oxide synthase. These inhibitors appear to be
specific for nitric oxide synthase, although it has been reported that some may
block muscarinic receptors (12). The inactive D-enantiomers of these arginine
analogs are also available and serve as useful controls. Several drugs serve as
nitric oxide donors; their action is not blocked by nitric oxide synthase inhibi-
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TABLE 1
Examples of Drugs Used to Investigate the L-Arginine/Nitric Oxide Pathway
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Name Abbreviation Action
L-arginine L-Arg
N_.monomethyl-L-arginine L-NMMA
N_.nitro_L_arginine L-NNA
N_-nitro-L-arginine methyl ester L-NAME
Sodium nitroprusside
3-Morpholinosydnonimine SIN- 1
S-Nitroso-N-acetyl-D,L-penicillamine SNAP
Hemoglobin
NO precursor
NOS inhibitor
NOS inhibitor
NOS inhibitor
NO donor
NO donor
NO donor
NO scavenger
tors. Finally, hemoglobin can be used as a nitric oxide scavenger. These drugs
have all been used to investigate the role of nitric oxide in the regulation of renin
and vasopressin secretion.
ROLE OF NITRIC OXIDE IN THE REGULATION OF RENIN SECRETION
Control of Renin Secretion
The rate at which renin is secreted by the juxtaglomerular cells in the afferent
arteriole of the kidneys is the major determinant of the activity of the renin-
angiotensin system, and the mechanisms that regulate renin secretion have been
studied extensively during the past three decades (28, 46, 55, 62, 114, 124).
Three major regulatory mechanisms have been identified and extensively, al-
though not completely, characterized. Several other factors including prostacyc-
lin and adenosine participate in the regulation of renin secretion; these may be
regulatory mechanisms in their own right or may serve as modulators of the
major control mechanisms.
Renin secretion is controlled by the renal baroreceptor, the macula densa, and
the sympathetic nervous system. In addition, angiotensin II exerts an important
negative feedback action on renin secretion.
Renal Baroreceptor
The renal baroreceptor monitors renal perfusion pressure and signals an
increase in renin secretion when perfusion pressure decreases (28, 46, 62). This
is a sensitive mechanism, and according to one analysis (46), renin secretion
doubles with every 2-3 mm Hg reduction in renal artery pressure below a
threshold of approximately 90 mm Hg. The pressure sensor appears be located in
the afferent arteriole. It may be located in the juxtaglomerular cells themselves,
although recent studies failed to provide evidence for this (104).
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Macula Densa
The macula densa serves as an NaC1 sensor which signals an increase in renin
secretion when the amount of NaC1 delivered to the distal nephron decreases
(28, 46, 62, 124). This mechanism involves an Na÷-K+-2C1 cotransporter
located in the luminal membrane of the macula densa cells (9, 68, 106). At the
present time, the signaling pathway between the macula densa and the juxtaglo-
merular cells is not known. Several substances have been proposed for this role,
including prostacyclin and adenosine (46, 55, 114). Nitric oxide may also play a
role and this possibility is discussed later in this review.
Sympathetic Nervous System
Norepinephrine released from renal sympathetic nerves stimulates renin
secretion by way of beta adrenoceptors thought to be located on the juxtaglomeru-
lar cells (28, 46, 62, 95). Most evidence indicates that the stimulation of renin
secretion is mediated by activation of adenylate cyclase and the formation of
cyclic adenosine 3',5'-monophosphate (cyclic AMP). Reflex increases in renal
sympathetic nerve activity stimulate renin secretion, while reductions in nerve
activity suppress it.
Signal Transduction
The signal transduction mechanisms involved in the control of renin secretion
have been studied extensively (20, 22, 29, 55, 66, 114). Two established intracel-
lular messengers are calcium and cyclic AMP. Calcium constitutes a major
inhibitory signal to renin secretion, and the increase in renin secretion that
results from activation of the renal baroreceptor is thought to be mediated by a
decrease in calcium concentration in the juxtaglomerular cells. Cyclic AMP is
another important intracellular messenger molecule which, as noted above,
mediates the renin secretory response to beta adrenoceptor stimulation.
Cyclic GMP has also been implicated in the regulation of renin secretion (46,
66, 114). This is particularly relevant to the present review because nitric oxide
is a potent stimulator of guanylyl cyclase activity. However, the role of cyclic
GMP remains an enigma, evidence having been presented that cyclic GMP
stimulates, inhibits, or has no effect on renin secretion (46, 50, 66, 85, 114).
Additional research is required to clarify the role of cyclic GMP in the regulation
of renin secretion.
Nitric Oxide and the Control of Renin Secretion
Studies utilizing renal cortical slices, isolated juxtaglomerular cells, and per-
fused kidneys have implicated endothelial factors in the control of renin secre-
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tion (16, 67, 80, 125). Subsequent studies revealed that one of these factors is
nitric oxide. As discussed above, the enzyme nitric oxide synthase and its mRNA
are present in the kidney, particularly in cells of the macula densa, a structure
that plays an important role in the control of renin secretion. Arginine analogs
that inhibit nitric oxide synthesis have been demonstrated to cause alterations
in renin secretion when administered to intact animals, perfused kidneys, or
renal tissue in vitro.
It now appears that nitric oxide not only contributes to the regulation of basal
renin secretion, but is also involved in the renin secretory responses to activation
of the major mechanisms that regulate renin secretion.
Basal Renin Secretion
Several investigators have studied the effect of blocking nitric oxide synthesis
on basal renin secretion. In many studies, acute blockade of nitric oxide synthe-
sis has resulted in suppression of renin secretion (21, 27, 31, 43, 57-59, 112)
(Fig. 3). The mechanisms responsible for this suppression of renin secretion
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FIG. 3. Effects of the nitric oxide synthase inhibitor L-NAME on mean arterial pressure (MAP),
heart rate (HR), and plasma renin activity (PRA). L-NAME (5 mg/kg) was injected intravenously at
0 min. Each point represents the mean _+ SEM of observations made in five conscious rabbits.
**p < 0.01 compared to the 0 min value.
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have not been conclusively identified. Blockade of nitric oxide synthesis in the
intact animal generally increases arterial pressure and this could conceivably
suppress renin secretion by increasing renal perfusion pressure or by causing a
reflex decrease in renal sympathetic nerve activity. Studies by Sigmon et al. (112)
provided support for such a pressure-dependent mechanism. They showed that
the suppression of renin secretion elicited by the nitric oxide synthase inhibitor
N'-nitro-a-arginine methyl ester (L-NAME, Table 1) in anesthetized rats could
be prevented by maintaining renal perfusion pressure constant and blocking
beta adrenoceptor effects on renin secretion with propranolol.
In marked contrast, Johnson and Freeman (57, 59) observed that controlling
renal perfusion pressure did not prevent L-NAME-induced suppression of renin
secretion in anesthetized rats. Moreover, these investigators (59) reported that
surgical denervation of the kidneys also failed to prevent the suppression of
renin secretion, whether or not renal perfusion pressure was held constant. The
reason for the discrepancy between the results of Sigmon et al. and those of
Johnson and Freeman is not apparent. Whatever the reason, it is clear that
inhibition of nitric oxide synthesis can suppress renin secretion in the absence of
the renal nerves and changes in renal perfusion pressure. For example, infusion
of nitric oxide synthase inhibitors in isolated rat kidneys inhibits renin release
even when the kidneys are perfused at constant pressure (41, 42, 80). Moreover,
it has been reported that inhibition of nitric oxide synthesis increases rather
than decreases renal sympathetic nerve activity (47, 100).
It is known that inhibition of nitric oxide synthesis can produce marked
alterations in renal hemodynamics and tubular function (3, 30, 32, 52, 53, 72, 88,
102) which could in turn cause alterations in renin secretion. However, inhibi-
tion of nitric oxide synthesis suppresses renin release by isolated juxtaglomeru-
lar cells cocultured with endothelial cells (67, 110) where such changes could not
be involved. Similarly, the nitric oxide precursor L-arginine and the nitric oxide
donors sodium nitroprusside and SIN-1 (Table 1) both stimulate renin release in
vitro (26, 110).
How then does inhibition of nitric oxide synthesis suppress renin secretion?
One possibility is that the inhibition results from an increase in cyclic AMP
metabolism by phosphodiesterase. It is now known that there are several
isoforms of phosphodiesterase, one of which (PDE III) is inhibited by cyclic GMP
(4, 23). As discussed above, nitric oxide donors increase renal cyclic GMP levels,
and this would be expected to inhibit PDE III, decrease cyclic AMP hydrolysis,
and increase renin secretion. Our recent observation that the PDE III inhibitor
milrinone increases resting renin secretion in rabbits (93) (Fig. 4) is consistent
with this proposal. Conversely, inhibition of nitric oxide synthesis would de-
crease renal cyclic GMP levels, resulting in disinhibition of PDE III, increased
cyclic AMP hydrolysis, and suppression of renin release. Our finding that
milrinone prevents the suppression of renin secretion by L-NAME (92) provides
support for such a mechanism. The possible role of PDE III is discussed in more
detail below in the section on nitric oxide and beta adrenoceptor control of renin
secretion.
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FIG. 4. Effects of the phosphodiesterase III inhibitor milrinone on mean arterial pressure
(MAP), heart rate (HR), and plasma renin activity (PRA). Milrinone (10 txg/kg/min) or the saline
vehicle was infused intravenously from 0 to 30 min. Each point represents the mean _+ SEM of
observations made in 12 conscious rabbits. **p < 0.01 compared to the 0 min value.
In other studies, blockade of nitric oxide synthesis has been found to increase
renin secretion. For example, chronic administration of nitric oxide synthase
inhibitors increased plasma renin activity in rats (97) and dogs (101). Nitric
oxide synthase inhibitors also increased renin release when infused intrarenally
in dogs (117) or when added to renal cortical slices in vitro (5). The reason that
inhibition of nitric oxide synthesis decreases renin secretion in some circum-
stances but increases it in others is not clear. Schricker and Kurtz (109) have
proposed that nitric oxide can exert both inhibitory and stimulatory actions on
renin secretion, but additional investigation is required.
In summary, studies of the effects of inhibition of nitric oxide on renin
secretion in several laboratories have clearly implicated nitric oxide in the
control of basal renin secretion. In most circumstances, inhibition of nitric oxide
synthesis suppresses renin secretion. The accompanying changes in blood pres-
sure or renal function may contribute to the suppression in vivo, but other
mechanisms must be involved because the suppression also occurs in vitro.
Changes in cyclic AMP metabolism may be involved. In other circumstances, for
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example,long-termtreatment,inhibitionof nitric oxidesynthesisincreases
reninsecretion.Further studyof thesechangesin reninsecretionandof the
mechanismsunderlyingthemisneeded.
Pressure-Dependent Renin Secretion
The renin secretory response to a decrease in renal perfusion pressure is
thought to be mediated by a reduction in calcium concentration in the juxtaglo-
merular cells (22, 66). Since nitric oxide decreases calcium concentration in
vascular smooth muscle and other cells, an interaction between nitric oxide and
the pressure control of renin secretion would be anticipated. Several groups of
investigators have now provided evidence for a role of nitric oxide in pressure-
dependent renin release.
Persson et al. (86) investigated the effect of inhibiting nitric oxide synthesis on
pressure-dependent renin release in conscious dogs. They assessed the renin
secretory response to step reductions in renal artery pressure to 50 mm Hg
under control conditions and following intravenous administration of L-NAME.
The results are shown in Fig. 5. L-NAME markedly attenuated pressure-
dependent renin secretion, especially in the tow pressure range, without signifi-
cantly altering the autoregulation of renal blood flow and glomerular filtration
rate.
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FIG. 5. Glomerular filtration rate (GFR), renal blood flow (RBF), and renin release during
step reductions in renal artery pressure (RAP) before and after administration of the nitric
oxide synthase inhibitor L-NAME in conscious dogs. Reproduced with permission from Persson et al.
(86).
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Althoughthe resultsof Perssonet al. clearly demonstrate that inhibition of
nitric oxide synthesis suppresses the renin response to renal hypotension, it is
important to note that L-NAME was administered intravenously in a dose which
caused a marked pressor response. Thus, it could be argued that the suppression
of the renin response resulted from a systemic effect of inhibition of nitric oxide
synthesis. For example, a reduction in renal sympathetic nerve activity could be
responsible as suggested by Sigmon et al. (112). On the other hand, Naess et al.
(82) observed that intrarenal infusion of another nitric oxide synthase inhibitor
L-NNA in anesthetized dogs, in a dose that did not alter systemic arterial
pressure, markedly suppressed the renin response to constriction of the renal
artery.
Additional evidence for an intrarenal site of action of nitric oxide synthase
inhibitors on renin secretion was provided by Scholz and Kurtz (108). They
observed that the renin response to reduction in renal artery pressure in isolated
rat kidneys was markedly attenuated by three inhibitors of nitric oxide synthe-
sis. Evidence was provided that this attenuation was specifically due to a
reduction in nitric oxide formation. These investigators also observed that
acetylcholine, a known stimulus to nitric oxide formation (70), enhanced the
renin response to reductions in renal perfusion pressure, particularly at low
perfusion pressures.
These studies clearly demonstrate that there is an interaction between nitric
oxide and pressure-dependent renin release. However, the source of this nitric
oxide and the mechanisms by which it influences pressure-dependent renin
release remain to be determined.
Beta Adrenoceptor Control of Renin Secretion
Although there is evidence that nitric oxide participates in the vasodilator
response to beta adrenoceptor stimulation (44, 127), there is little information
concerning possible interactions between nitric oxide and the beta adrenoceptor
control of renin secretion. Sigmon et al. (112) investigated the effect of L-NAME
in propranolol-treated anesthetized rats in which renal perfusion pressure was
held constant. In these circumstances, L-NAME increased renin secretion. They
proposed that L-NAME caused a stimulation of renin secretion that was counter-
acted by a reflex reduction in beta adrenoceptor stimulation of renin secretion in
response to the systemic effects of L-NAME. The possibility that there is an
interaction between nitric oxide and the beta adrenoceptor control of renin
secretion at the level of the kidney was not considered. However, subsequent
studies by Scholz and Kurtz (108) failed to provide evidence for such an
interaction. They found that blockade of nitric oxide synthesis in a perfused rat
kidney preparation did not alter the renin secretory response to beta adrenocep-
tor stimulation with isoproterenol. Only two kidneys were studied and results
were presented for only one of these.
In order to further investigate a possible role of nitric oxide in beta adrenocep-
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tor controlof reninsecretion,westudiedthe effectof inhibitingnitric oxide
synthesiswith L-NAMEon the reninsecretoryresponseto betaadrenoceptor
stimulationwith isoproterenolinconsciousrabbits(91).Theresultsaresumma-
rizedin Fig.6. Infusionof isoproterenolaloneincreasedplasmareninactivity
andheartrate.Pretreatmentwith L-NAMEreducedtheheartrateresponseto
isoproterenolandinhibitedthe renin response.Therenin andheartrate re-
sponsescouldbepartiallyor fully restoredbyadministrationofthenitricoxide
donornitroprusside,providingevidencethattheeffectsof [,-NAME were due to
inhibition of nitric oxide synthesis. These findings provide evidence that nitric
oxide participates in the renin secretory and heart rate responses to beta
adrenoceptor stimulation. Moreover, the finding that the renin and heart rate
responses to isoproterenol could be restored by nitroprusside indicates that the
responses are not mediated by nitric oxide, but that the presence of nitric oxide is
required in order for the responses to be manifested.
There are several possible mechanisms by which inhibition of nitric oxide
synthesis could attenuate the renin secretory response to isoproterenol. L-
NAME increases arterial pressure and this could inhibit the renin response to
isoproterenol by activating the renal baroreceptor mechanism or by causing a
reflex reduction in renal sympathetic nerve activity. However, the pressor effect
of L-NAME in our experiments was small (6-10 mm Hg) and during infusion of
isoproterenol, mean arterial pressure was not significantly higher in the pres-
ence of L-NAME than in its absence (Fig. 6). Furthermore, we have found that
administration of the same dose of L-NAME in conscious rabbits causes little or
no reduction in renal sympathetic nerve activity (K. Kumagai and I. A. Reid,
unpublished observations), and others have reported that inhibition of nitric
oxide synthesis in anesthetized rats increases rather than decreases renal
sympathetic nerve activity (47, 100). Nevertheless, to investigate if the pressor
action of L-NAME could be responsible for the attenuation of the renin response
to isoproterenol, we tested the effect of producing a similar increment in blood
pressure with an infusion of phenylephrine. The results are summarized in Fig.
7. Phenylephrine produced the same increase in blood pressure as L-NAME, but
did not significantly alter the renin or heart rate responses to isoproterenol.
Thus, it is unlikely that the pressor effect of L-NAME was responsible for the
suppression of the renin response to isoproterenol.
As discussed above, it is now generally accepted that the renin secretory
response to isoproterenot is mediated by beta adrenoceptors coupled to adenylate
cyclase and the generation of cyclic AMP. It was therefore of interest that
Klabunde et al. (64) reported that the increase in cardiac cyclic AMP concentra-
tion induced by isoproterenol was reduced by the nitric oxide synthase inhibitor
L-NMMA. They also observed that L-NMMA decreased cardiac cyclic GMP
concentration and suggested that this resulted in disinhibition of the cyclic
GMP-inhibitable isoform of cyclic AMP phosphodiesterase (PDE III) which in
turn increased hydrolysis of cyclic AMP. As shown in Fig. 8, a similar mechanism
could explain the suppression of the renin response to isoproterenol.
Central to the scheme proposed in Fig. 8 is the enzyme PDE III. This enzyme
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FIG. 6. Effects of intravenous isoproterenol infusion on mean arterial pressure (MAP}, heart
rate (HR), and plasma renin activity (PRA) during intravenous infusion of L-NAME or the saline
vehicle. Infusion of I,-NAME (0.5 mg/kg/min) or the saline vehicle was started immediately after
completion of control measurements at -15 min and continued throughout the experiment.
Isoproterenol (0.02 ixg/kg/min) was infused from 0 to 30 min. Values represent the mean -+ SEM
of observations made in eleven conscious rabbits. +p < 0.05 compared to the -15 min value.
*p < 0.05, **p < 0.01 compared to the 0 min value. Slightly modified from Reid el al. {91 ).
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FIG. 7. Effects of intravenous isoproterenol infusion on mean arterial pressure (MAP), heart
rate (HR), and plasma renin activity (PRA) during intravenous infusion of phenylephrine or the
saline vehicle. Infusion of phenytephrine (0.5-2.0 _g/kg/min) or the saline vehicle was started
immediately after completion of control measurements at - 15 min and continued throughout the
experiment. Isoproterenol (0.02 p.g/kg/min) was infused from 0 to 30 min. Values represent the
mean -+ SEM of observations made in eight conscious rabbits. +p < 0.05 compared to the -15 min
value. *p < 0.05, **p < 0.01 compared to the 0 min value.
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FIG. 8. Hypothetical mechanism by which inhibition of nitric oxide synthesis with L-NAME
could suppress the renin secretory response to beta adrenoceptor stimulation with isoproterenol
(ISO). According to this hypothesis, L-NAME decreases nitric oxide synthesis in the vicinity of the
juxtaglomerular cells. As a result, soluble guanylyl activity and cyclic GMP concentration in the
juxtaglomerular cells decrease. The inhibition of the cyclic GMP-inhibitable phosphodiesterase (PDE
III) is removed, and hydrolysis of cyclic AMP increases. Consequently, both basal renin secretion and
the renin response to ISO decrease. Broken arrow indicates inhibition.
contributes to cyclic AMP hydrolysis in the pulmonary circulation, heart, smooth
muscle, adipose tissue, and platelets (48, 81, 84). PDE III is present in the kidney
(74), but it is not known if it participates in the regulation of cyclic AMP
concentration in, and renin secretion by, the juxtaglomerular cells. If PDE III
does participate in the regulation of the renin secretion, it would be predicted
that inhibition of the enzyme would increase renin secretion and potentiate the
renin secretory response to beta adrenoceptor stimulation.
Recently, we tested this prediction in conscious rabbits using the specific PDE
III inhibitor milrinone (93). As shown in Fig. 4, infusion of milrinone increased
renin secretion without changing blood pressure. Milrinone also potentiated the
renin response to intravenous infusion of isoproterenol. In this context, it is of
interest that Downing et al. (33) have reported that inhibition of PDE III
potentiates beta-adrenoceptor-dependent secretion ofprorenin by human placen-
tal explants. Finally, milrinone inhibited the suppression of renin secretion in
response to infusion of L-NAME. This last observation suggests that the suppres-
sion of renin secretion by L-NAME results from disinhibition of PDE III and an
increase in cyclic AMP hydrolysis in thejuxtaglomerular cells. However, measure-
ments of renal cyclic AMP and cyclic GMP levels are needed to test the proposal
more directly.
In summary, our results provide evidence that there is an interaction between
nitric oxide and the beta adrenoceptor control of renin secretion. Our results also
suggest that this interaction involves changes in cyclic AMP hydrolysis by the
cyclic GMP-inhibitable isoform of cyclic AMP phosphodiesterase.
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Macula Densa Control of Renin Secretion
The presence of a high concentration of nitric oxide synthase in the macula
densa has stimulated interest in the possibility that nitric oxide is involved in the
macula densa control of renin secretion. He et al. (49) investigated the effect of
arginine and the nitric oxide synthase inhibitor L-NNA on renin release by an
isolated rabbit juxtaglomerular apparatus preparation. Addition of arginine to
the tubular lumen increased renin secretion, while addition of L-NNA markedly
reduced the renin responses to changes in macula densa NaC1 concentration.
The results provide evidence that nitric oxide, possibly originating in the macula
densa, can act as a stimulatory factor in the control of renin secretion.
Recently, we investigated the effect of inhibiting nitric oxide synthesis with
L-NAME on the renin secretory response to administration of the diuretic
furosemide in conscious rabbits (94). Most evidence indicates that furosemide,
when administered acutely, stimulates renin secretion by an action on the
macula densa. In vivo, the stimulation of renin secretion occurs without de-
creases in blood volume or blood pressure (39, 75) and is not prevented by beta
adrenoceptor blockade (39, 56). In vitro, furosemide stimulates renin secretion
by microdissected afferent arterioles with the macula densa attached but not
from afferent arterioles alone (54). Recent evidence indicates that the stimula-
tion of renin secretion by furosemide results from inhibition of Na÷-K+-2C1 -
cotransport in the macula densa (9, 19, 68, 106).
The results of our experiments are shown in Fig. 9. Before L-NAME, there
were significant increases in plasma renin activity 15, 30, and 45 min after
furosemide; following administration of L-NAME; however, there was only a
small increase at 15 min. In control experiments, infusion of phenylephrine in a
dose that produced the same increase in arterial pressure as L-NAME did not
inhibit the renin response to furosemide. Based on these results, we proposed
that L-NAME inhibits the renin response to furosemide by blocking nitric oxide
synthesis in the kidney. These results are consistent with those of He et al. (49)
and with the hypothesis that nitric oxide participates in the macula densa
control of renin secretion.
How could the L-arginine/nitric oxide pathway in the macula densa participate
in the control of renin secretion? More specifically, do alterations in Na÷-K ÷-
2C1- cotransport alter macula densa nitric oxide synthase activity and, if so, do
the resulting changes in nitric oxide synthesis affect renin secretion?
With regard to the first question, it is known that the constitutive forms of
nitric oxide synthase require calcium for activity (38, 65), and there is evidence
that a reduction in macula densa NaC1 concentration increases cytosolic free
calcium concentration in cells of the macula densa (103). Thus, it would be
anticipated that a decrease in Na÷-K÷-2C1 - cotransport would increase nitric
oxide synthase activity in the macula densa. To test this prediction, we investi-
gated the effect of administration of furosemide on nitric oxide synthase activity
in the macula densa. In these experiments, rabbits received an intravenous
injection of furosemide (20 mg/kg) (n = 3) or the saline vehicle (n = 3). After 30
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FIG. 9. Effect of intravenous furosemide on mean arterial pressure, heart rate, and plasma renin
activity during intravenous infusion of L-NAME or the saline vehicle. Intravenous infusion of
[,-NAME (0.5 mg/kg/min) or the saline vehicle was started immediately after completion of control
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injected at 0 min. Note that the maximum renin response to administration of L-NAME occurs
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in 12 conscious rabbits. +p < 0.05, ++p < 0.01 compared to the -15 min value. *p < 0.05,
**p < 0.01 compared to the 0 rain value.
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min, the kidneys were removed and processed for NADPH diaphorase histochem-
istry. Representative kidney sections from control and furosemide-treated rab-
bits are shown in Fig. 10. There was a clear increase in staining intensity in
macula densas of furosemide-treated rabbits. Since, as noted above, furosemide
inhibits Na÷-K÷-2C1 - cotransport in the macula densa, these results are consis-
FIG. 10. NADPH diaphorase staining of sections of kidneys from control (top) and furosemide-
treated (bottom) rabbits. G, glomerulus, MD, macula densa; PT, proximal tubule; DT, distal tubule.
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tent with the proposal that a reduction in macula densa NaC1 transport in-
creases nitric oxide synthase activity in the macula densa.
With regard to the second question, it is possible that nitric oxide generated in
the macula densa diffuses into the adjacent juxtaglomerular cells where it could
increase cyclic GMP concentration which, in turn, could stimulate renin secre-
tion, possibly by decreasing the intracellular calcium concentration. The prob-
lem here is that while many studies indicate that nitric oxide and/or cyclic GMP
stimulate renin secretion, others suggest that these substances inhibit or have
no effect on renin secretion (46, 50, 66, 85, 114). As noted earlier, this issue needs
to be resolved.
The results of a recent study by Tsukahara et al. (123) are particularly
relevant to the hypothesis that nitric oxide participates in the macula densa
regulation of renin secretion. These investigators observed that a reduction in
ambient chloride concentration caused an increase in cytosolic calcium concen-
tration and a calcium/calmodulin-dependent increase in nitric oxide production
in cultured rat mesangial cells. They proposed that this nitric oxide could serve
to link changes in macula densa ion transport to changes in afferent arteriolar
resistance and renin secretion. As they pointed out, nitric oxide released by
mesangial cells could augment nitric oxide produced by macula densa cells.
Ifa reduction in macula densa NaC1 transport increases nitric oxide synthesis,
it might be anticipated that the converse would be true. Studies by other
investigators (31, 120) indicate that dietary salt loading increases, rather than
decreases, renal nitric oxide production. However, the site in the kidney at which
this increase in nitric oxide production occurs remains to be determined.
Of course, it is important to point out that although our results are consistent
with a role for nitric oxide in the macula densa control of renin secretion, they by
no means prove it. It is possible, for example, that the action of L-NAME to
suppress the renin secretory response to furosemide results from blockade of
nitric oxide synthesis in cells other than those of the macula densa such as
mesangial (123), endothelial, or other cells. Nevertheless, the fact that there is
abundant nitric oxide synthase in the macula densa together with our observa-
tion that the activity of this enzyme is apparently increased by furosemide
warrants additional investigation of the role of the macula densa L-arginine/
nitric oxide pathway in the regulation of renin secretion.
Summary: Renin
Several lines of evidence implicate nitric oxide in the control of renin secretion.
Nitric oxide synthase is present in vascular and tubular elements of the kidney,
particularly in cells of the macula densa, a structure that plays an important role
in the control of renin secretion. Guanylyl cyclase, a major target for nitric oxide
is also present in the kidney. Drugs that inhibit nitric oxide synthesis generally
suppress renin release both in vivo and in vitro, suggesting a stimulatory role for
the L-arginine/nitric oxide pathway in the control of renin secretion. Under
some conditions, however, nitric oxide apparently inhibits renin secretion. It
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nowappearsthat nitric oxidenot onlycontributesto theregulationof basal
reninsecretion,but alsoparticipatesin thereninsecretoryresponsesto activa-
tionoftherenalbaroreceptor,maculadensa,andbetaadrenoceptormechanisms
thatregulatereninsecretion.
ROLE OF NITRIC OXIDE IN THE REGULATION OF VASOPRESSIN SECRETION
Biosynthesis and Secretion of Vasopressin
Vasopressin is synthesized in magnocellular neurons in the supraoptic and
paraventricular nuclei of the hypothalamus. It is packaged into secretory gran-
ules and transported to the posterior pituitary, where it is stored in nerve
terminals and released into the systemic circulation.
The release of vasopressin is controlled by osmotic and reflex mechanisms
(40). Stimuli to vasopressin secretion including water deprivation and salt
loading act predominantly by way of central osmoreceptors thought to be located
in a circumventricular organ, the organum vasculosum of the lamina terminalis.
Other stimuli including hypovolemia and hypotension act by way of arterial
baroreceptors located in the carotid sinus and aortic arch, and stretch receptors
located in the left and right atria. Vasopressin secretion is also stimulated by
anesthetics and other pharmacological agents, stress, pain, nausea and vomit-
ing, and angiotensin II.
Nitric Oxide Synthase in the Hypothalamus and Pituitary
Sagar and Ferriero (99) first demonstrated that magnocellular neurons of the
supraoptic and paraventricular nuclei of the rat hypothalamus, the sites of
vasopressin synthesis, stain positively for NADPH diaphorase. Their observa-
tion was subsequently confirmed by other investigators using both light (1, 13,
14, 60, 87, 105) and electron (15) microscopy. Sagar and Ferriero (99) also
observed strong diaphorase staining in the posterior pituitary, the site of
vasopressin storage and secretion; lighter staining was observed in the interme-
diate and anterior lobes.
Bredt et al. (7) localized nitric oxide synthase protein in the rat brain by
immunocytochemistry using antisera raised against the purified enzyme. They
observed intense staining of cell bodies in the supraoptic and paraventricular
nuclei and in nerve fibers and terminals in the posterior lobe of the pituitary
(Fig. 11). As reported by Sagar and Ferriero (99), only weak staining was
observed in the intermediate and anterior lobes. Subsequently, Bredt and his
associates demonstrated the presence of the mRNA for nitric oxide synthase in
supraoptic magnocellular neurons (6). They also showed that nitric oxide syn-
thase and NADPH diaphorase are colocalized throughout the brain.
Calka and Block (14) and Sandez et al. (105) compared the distribution of
vasopressin and NADPH diaphorase in the rat hypothalamus using immunocy-
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FIG. 11. Immunohistochemical localization of nitric oxide synthase in the pituitary (top),
supraoptic nucleus (center), and paraventricular nucleus (bottom). A, anterior lobe; I, intermediate
lobe; P, posterior lobe; SO, supraoptic nucleus; OX, optic chiasm; ON, optic nerve; V, third ventricle.
Reproduced with permission from Bredt et al. (7).
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tochemistry and histochemistry. Double labeling of a small number of neurons
was observed in the supraoptic and paraventricular nuclei. Other investigators
have observed colocalization of vasopressin and NADPH in these nuclei, al-
though only a small number of neurons (76, 121). Interestingly, colocalization of
oxytocin with NADPH occurs more frequently (76, 121) and this observation,
together with other evidence (17, 116), suggests a role for nitric oxide in the
control of oxytocin secretion.
Recently, Villar et al. (126) reported that nitric oxide synthase immunoreactiv-
ity and mRNA levels in magnocellular neurons of the supraoptic and paraven-
tricular nuclei of rats increase after hypophysectomy. Since there is evidence
that nitric oxide participates in the regulation of hypothalamic portal blood flow
(18), Villar et al. reasoned that increased nitric oxide production after damage to
neurosecretory axons might increase portal blood flow and promote regeneration
of the neural lobe.
Effects of Changes in Salt and Water Balance on Hypothalamic and
Pituitary NADPH Activity
Alterations in sodium and water balance have been observed to cause changes
in NADPH activity in the hypothalamus and/or posterior pituitary. Sagar and
Ferriero (99) reported that 8 days of salt loading in rats increased NADPH
diaphorase activity in the posterior pituitary, but not in the hypothalamus. Pow
(87) reported that "dehydration of rats for 12 h" caused a large and rapid
increase in diaphorase staining in the supraoptic nucleus. Calka et al. (15)
localized NADPH diaphorase in the rat supraoptic nucleus by electron micros-
copy. They observed no significant change in mitochondrial diaphorase staining
after 12 h of dehydration, but a "noticeable increase" after 9 days.
These observations demonstrate that nitric oxide synthase is present in the
supraoptic and paraventricular nuclei and the posterior pituitary gland, that it
can be colocalized with vasopressin, and that its activity can be altered by
changes in salt and water balance.
Nitric Oxide and Vasopressin Release: In Vitro Studies
Recent in vitro studies have provided evidence for a role of nitric oxide in the
control of vasopressin release. Yasin et al. (130) studied the effects of nitric oxide
donors on basal and stimulated vasopressin release by hypothalamic explants.
The nitric oxide precursor L-arginine reduced KCl-evoked vasopressin release
and this effect was reduced by the nitric oxide synthase inhibitor L-NMMA as
well as by ferrous hemoglobin. L-arginine also reduced interleukin-l[_-stimu-
lated vasopressin release. The nitric oxide donors SIN-1 and sodium nitroprus-
side (Table 1) both attenuated KCl-evoked vasopressin release.
Lutz-Bucher and Koch (71) investigated the effect of changes in nitric oxide
synthesis on vasopressin release from the isolated neural lobe of the rat pituitary
gland. Blockade of nitric oxide synthesis with L-NAME, or inactivation of nitric
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oxidewith ferroushemoglobin,increasedvasopressinrelease.L-arginine,but
not o-arginine,and SIN-1dampenedthe releaseof vasopressinevokedby
L-NAME.
Thesetwoin vitro studies suggest that nitric oxide plays an inhibitory role in
the control of vasopressin release and that this action is exerted both at the level
of the hypothalamus and pituitary.
Nitric Oxide and Vasopressin Release: In Vivo Studies
Well before the importance of nitric oxide in the brain was first appreciated,
Eriksson et al. (37) investigated the effect of infusing L-arginine into a lateral
cerebral ventricle of hydrated goats. They observed that L-arginine caused a
decrease in free water clearance in association with an increase in urinary
vasopressin excretion. Another basic amino acid, L-lysine, was inactive. Inas-
much as L-arginine is the endogenous precursor of nitric oxide, these observa-
tions suggest that nitric oxide can stimulate vasopressin release in vivo. Obvi-
ously, however, the effect of a nitric oxide synthase inhibitor on the responses to
L-arginine needs to be tested.
In subsequent in vivo studies, the role of nitric oxide in the control of
vasopressin secretion has been investigated in rats, rabbits, and dogs.
Rat
Ota et al. (831) observed that intracerebroventricular injection of the nitric
oxide donor SNAP (Table 1) in conscious, chronically prepared rats caused
transient dose-related increases in plasma vasopressin concentration. Injection
of L-arginine also increased plasma vasopressin concentration. In control experi-
ments, injection of N-acetylpenicillamine, the inactive precursor of SNAP, or
D-arginine elicited only very small increases in plasma vasopressin concentra-
tion. Based on these results, it was concluded that nitric oxide inhibits vasopres-
sin secretion.
On the other hand, Summy-Long et al. (116) were unable to demonstrate a
role for nitric oxide in the secretion of vasopressin during dehydration. They
observed that intracerebroventricular injection of two inhibitors of nitric oxide
synthase in rats following 24 h water deprivation failed to alter plasma vasopres-
sin concentration, although there was an increase in plasma oxytocin concentra-
tion.
Recent studies by Kadowaki et al. (60) suggest that endogenous nitric oxide
exerts an inhibitory action on vasopressin secretion. These investigators studied
the effect of salt loading on nitric oxide synthase and vasopressin gene expres-
sion in the rat hypothalamohypophyseal system. Salt loading is a potent stimu-
lus to vasopressin secretion which results in marked depletion of vasopressin
from the posterior pituitary. During 4 days of salt loading, there were marked
increases in nitric oxide synthase (Fig. 12) and vasopressin mRNA levels, and
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FIG. 12. Nitric oxide synthase (NOS) mRNA concentration in the supraoptic nucleus (SON),
paraventricular nucleus (PVN), and central amygdaloid nucleus (AMG) of control and 4-day
salt-loaded rats. Reproduced by permission from K. Kadowaki, J. Kishimoto, G. Leng, and P. C.
Emson. Endocrinology 1994; 134: 1011-1017.
NADPH diaphorase staining in the supraoptic and paraventricular nuclei. The
increase in nitric oxide synthase mRNA levels was apparently specific to these
two hypothalamic nuclei because nitric oxide synthase mRNA levels did not
change in the medial amygdaloid nucleus (Fig. 12) or in brain areas outside the
hypothalamus.
The changes in hypothalamic nitric oxide synthase mRNA levels and diapho-
rase staining observed by Kadowaki et al. were accompanied by increases in
nitric oxide synthase mRNA levels and nitric oxide synthase enzyme activity in
the posterior pituitary. Intraperitoneal administration of the nitric oxide syn-
thase inhibitor L-NNA, which is known to inhibit brain nitric oxide synthase
(35), resulted in dose-related reductions in nitric oxide synthase activity in the
posterior pituitary of salt-loaded rats. It also decreased the already low posterior
pituitary vasopressin content (Fig. 13). In contrast, L-NNA did not alter pitu-
itary vasopressin content in normally hydrated rats. Based on these results,
Kadowaki et al. proposed that nitric oxide plays a neuromodulatory role to
restrain the vasopressin response to osmotic stimulation.
Rabbit
In a recent study in this laboratory (43), we investigated the effect of inhibiting
nitric oxide synthase with L-NAME on vasopressin secretion in conscious chroni-
cally prepared rabbits. The cardiovascular and endocrine effects of L-NAME are
summarized in Fig. 14. Fifteen to twenty minutes after intravenous injection of
L-NAME there was a twofold increase in plasma vasopressin concentration. The
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FIG. 13. Effect of the nitric oxide synthase inhibitor N-Arg (L-NNA) on the vasopressin content
of the posterior pituitary of rats during salt loading. Reproduced by permission from K. Kadowaki, J.
Kishimoto, G. Leng, and P. C. Emson. Endocrinology 1994; 134: 1011-1017.
increase in plasma vasopressin concentration was accompanied by an increase in
arterial blood pressure and decreases in heart rate and plasma renin activity.
This is a fairly modest increase in plasma vasopressin concentration, but two
points should be considered. First, the increase occurred despite the accompany-
ing increase in arterial pressure and decrease in plasma renin activity which
would normally be expected to inhibit vasopressin secretion. Second, increases in
plasma vasopressin concentration of this magnitude are sufficient to decrease
urine flow (2), cause vasoconstriction (96), and inhibit renin secretion (90).
Indeed, it is possible that the increase in plasma vasopressin contributed to the
increase in blood pressure and decrease in plasma renin activity observed in this
study. Our finding that L-NAME increased plasma vasopressin concentration is
consistent with other observations described above which suggest that nitric
oxide exerts a tonic inhibitory action on vasopressin secretion.
In contrast to its action on resting plasma vasopressin concentration, L-NAME
did not alter the vasopressin responses to infusion of hypertonic saline or
nitroprusside, nor did it alter the slope of the relationship between plasma
vasopressin concentration and plasma osmolality (Fig. 15) or between plasma
vasopressin concentration and mean arterial pressure. In another study (21), we
observed that L-NAME did not alter the vasopressin response to hypotensive
hemorrhage. Thus, although nitric oxide may be involved in the regulation of
basal vasopressin secretion in the rabbit, it does not appear to participate in the
vasopressin responses to acute changes in plasma osmolality, blood pressure, or
blood volume. Nevertheless, in view of the observation that in rats nitric oxide
synthase activity increases in the hypothalamus and pituitary during chronic
salt loading (99) and dehydration (87), it will be of interest to determine if the
vasopressin responses to these stimuli in rabbits are altered by inhibition of
nitric oxide synthesis.
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Dog
Manning et al. (73) observed that blockade of nitric oxide synthesis with
L-NAME in conscious dogs caused a marked reduction in urine flow. This
decrease was almost completely prevented by a vasopressin V1 receptor antago-
nist. They suggested that L-NAME increased vasopressin release which in turn
sequentially decreased vasa recta blood flow, renal interstitial hydrostatic pres-
sure, and urine flow, effects which would be prevented by blockade of vasopres-
sin V1 receptors (131). However, as they acknowledged, the L-NAME-induced
diuresis may have resulted from changes other than increased vasopressin
secretion. Indeed, Elsner et al. (36) previously reported that although blockade
of nitric oxide synthesis with L-NNA decreased urine flow in conscious dogs, it
did not change plasma vasopressin concentration. Thus, further investigation is
required to determine the mechanism by which blockade of nitric oxide synthesis
decreases urine flow, and if increases in vasopressin secretion contribute to this
response.
Summary: Vasopressin
Histochemical and immunocytochemical studies have clearly established that
nitric oxide synthase is present in the supraoptic and paraventricular nuclei of
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the hypothalamus and in the posterior pituitary. Colocalization of nitric oxide
synthase and vasopressin have been demonstrated, although only in a small
number of neurons. Nitric oxide synthase activity in the hypothalamus and
pituitary is increased by maneuvers known to stimulate vasopressin secretion,
including salt loading and dehydration. Administration of L-arginine and nitric
oxide donors in vitro and in vivo have produced variable effects on vasopressin
secretion but the most consistent one appears to be inhibition. Blockade of nitric
oxide synthesis has been reported to increase vasopressin secretion, but again
variable results have been obtained. One attractive working hypothesis proposed
by Kadowaki et al. (60) is that nitric oxide serves a neuromodulatory role as an
inhibitor of vasopressin secretion.
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